Recently, Professor Dong Zigang’s team at Zhengzhou University/China-US (Henan) Hormel Cancer Institute has made new progress in the field of esophageal squamous cell carcinoma drug therapy research. The study has revealed the key role of Galectin-1 in ESCC paclitaxel resistance, with the proposal that the elevated level of Galectin-1 in serum can be used as a biomarker to predict the response of ESCC patients to paclitaxel treatment, and that the resistance to paclitaxel treatment can be effectively reversed by targeting Galectin-1.